Gender disparities have been observed in the use of intravenous (IV) tissue plasminogen activator (tPA) for acute ischemic stroke, one of the few known treatments to improve long-term outcomes in this condition.1–5 In addition, women are less likely to meet quality markers for stroke: they are less likely to have non-contrast computed tomography (CT) within 25 minutes and to receive IV tPA within one hour.3,6. The gene discussed is PLAT; the disease is Stroke.